15+ key players and Out of all the emerging therapies, HBI-8000 is expected to capture the maximum patient pool owing to its immunomodulatory function. This oral agent targets class I histone deacetylase causing cell cycle arrest and tumor cell death as the mechanism underlying its single-agent activity against lymphoma. T-cell Leukemia pipeline comprises ASTX 660 (Otsuka Pharmaceutical) is in phase I/II while Valemetostat and Brentuximab vedotin (Seagen/Takeda) is in Phase II stage of development. HUYA Bioscience appears to have an upper edge as its therapy, HBI-8000 which is in the pre-registration phase. In April 2021, Shorla Pharma announced that the U.S. Food and Drug Administration (FDA) has accepted the filing application of its oncology drug